KR970042591A - 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법 - Google Patents

트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법 Download PDF

Info

Publication number
KR970042591A
KR970042591A KR1019950047617A KR19950047617A KR970042591A KR 970042591 A KR970042591 A KR 970042591A KR 1019950047617 A KR1019950047617 A KR 1019950047617A KR 19950047617 A KR19950047617 A KR 19950047617A KR 970042591 A KR970042591 A KR 970042591A
Authority
KR
South Korea
Prior art keywords
solution
protein
trehalose
stabilizer
heat treatment
Prior art date
Application number
KR1019950047617A
Other languages
English (en)
Other versions
KR0182395B1 (ko
Inventor
김희철
허재욱
장신재
이정식
성학모
정순관
Original Assignee
권계홍
주식회사 녹십자
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 권계홍, 주식회사 녹십자 filed Critical 권계홍
Priority to KR1019950047617A priority Critical patent/KR0182395B1/ko
Publication of KR970042591A publication Critical patent/KR970042591A/ko
Application granted granted Critical
Publication of KR0182395B1 publication Critical patent/KR0182395B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2780/00—Naked RNA viruses
    • C12N2780/00011—Details
    • C12N2780/00061—Methods of inactivation or attenuation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 단백질을 주성분으로 하는 의약품 생산시, 수용액 상태의 시료를 가열처리(섭씨 60℃, 10시간)에 의한 각종 바이러스 불활화시에 트레할로스(D-(+)-Trehalose)를 안정제로 사용하는 액상가열처리방법에 관한 것이다. 트레할로스 농도를 10-100w/v %로 조정하고 pH 5.0-9.0, 섭씨 40-70℃에서 적당한 농도의 단백질을 액상 가열처리시 단백질의 생리활성은 충분히 유지하면서 바이러스를 불화화시킨다. 트레할로스를 안정제로 사용하는 경우 기존의 안정제로서 사용되는 당류에 비해 가열 후에도 단백질의 2차 구조에 가장 적은 변화를 나타내었다.

Description

트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 안정제로서 트레할로스를 함유한 피브리노겐 용액의 액상가열 처리전과 후의 회전이선광 스펙트럼을 나타낸 것이다.

Claims (4)

  1. 단백질을 주성분으로 하는 용액의 바이러스 불활화시 안정화제로서 10-100w/v%의 트레할로스를 첨가하여 가열 처리함을 특징으로 하는 단백질용액의 액상가열처리방법.
  2. 제1항에 있어서, 단백질 용액이 피브리노겐 용액, 면역글로불린 지용액, 혈액응고 제8인자 용액, 혈액응고 제9인자 용액, 혈액응고 제13인자 용액, 유로키나아제 용액, 인뇨 유래 트립신 저해제 용액중에서 선택된 일종임을 특징으로 하는 단백질용액의 액상가열처방법.
  3. 제1항에 있어서, 첨가되는 트레할로스의 양이 바람직하게는 40-90w/v%임을 특징으로 하는 단백질 용액의 액상가열처리방법.
  4. 제1항에 있어서, 단백질 용액의 pH가 5.0-9.0 임을 특징으로 하는 단백질용액의 액상가열처리방법.
KR1019950047617A 1995-12-08 1995-12-08 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법 KR0182395B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019950047617A KR0182395B1 (ko) 1995-12-08 1995-12-08 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019950047617A KR0182395B1 (ko) 1995-12-08 1995-12-08 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법

Publications (2)

Publication Number Publication Date
KR970042591A true KR970042591A (ko) 1997-07-24
KR0182395B1 KR0182395B1 (ko) 1999-04-01

Family

ID=19438416

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950047617A KR0182395B1 (ko) 1995-12-08 1995-12-08 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법

Country Status (1)

Country Link
KR (1) KR0182395B1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100588952B1 (ko) * 1997-12-09 2006-10-13 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 혈액순환개선제

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100588952B1 (ko) * 1997-12-09 2006-10-13 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 혈액순환개선제

Also Published As

Publication number Publication date
KR0182395B1 (ko) 1999-04-01

Similar Documents

Publication Publication Date Title
US5099003A (en) Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii
EP0431129A4 (en) Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
ATE57474T1 (de) Ozonentkeimung von blut und blutprodukten.
JPS6236502B2 (ko)
US5639730A (en) Method of producing a virus-safe biological preparation
DE69718612T2 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
DK156698B (da) Fremgangsmaade til pasteurisering af et materiale indeholdende et termisk foelsomt, terapeutisk aktivtprotein valgt blandt alfa-l-antitrypsin, antithrombin-iii, praekallikrein, antihaemofil faktor (faktorviii) og fibronectin
DE3061547D1 (en) Process of preparation of an intravenous immunoglobulin solution, containing concentrated igm
CA1196281A (en) Heat stabilization of plasma proteins
EP0041173B2 (en) Blood-coagulation-promoting products and methods of preparing them
KR870010188A (ko) 핵산 또는 엔도톡신의 제거제 및 제거방법
ATE233576T1 (de) Wärmebehandlung von blutplasmaproteinen
KR950010321B1 (ko) 인간 트롬빈 제제의 가열처리방법
NO913129L (no) Nytt trombolytisk middel.
KR970042591A (ko) 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법
FR2701263B1 (fr) Procédé d'obtention d'une composition aqueuse protéinique, composition correspondante, glycoprotéine contenue et son utilisation pour la stabilisation de l'albumine et la détection ou le dosage d'anticorps.
ATE120645T1 (de) Verfahren und therapeutische zubereitungen für die behandlung von gerinnungsstörungen.
AU2002222283A1 (en) Fat replacement material and method of manufacture thereof
BR9303903A (pt) Fator-4 de plaqueta modificado ou clivado e processo para sua preparaçao, formulaçao farmacêutica, composto e vetor de dna recombinante e célula hospedeira
US5118795A (en) Sequential heat treatment of blood-clotting factor products
Koretz et al. Analysis of the factors involved in the loss and restoration of the chaperone-like function of α-crystallin
Von Zabern et al. Effect of different sulfonamides on the human serum complement system
JPS6210019A (ja) 人血液凝固第９因子含有製剤の加熱処理方法
JPH0725696B2 (ja) プラスミノ−ゲンの安定化方法
JPS6140392B2 (ko)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121011

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20130911

Year of fee payment: 16

LAPS Lapse due to unpaid annual fee